Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Rashmi Kanagal-Shamanna1, Guillermo Montalban-Bravo2, Panagiotis Katsonis3, Koji Sasaki2, Caleb A. Class4, Elias Jabbour5, David Sallman6, Anthony Michael Hunter3, Christopher Benton7, Kelly S. Chien8, Rajyalakshmi Luthra3, Carlos E. Bueso-Ramos1, Tapan Kadia2, Michael Andreeff5, Ramzi S. Kornokji5, Najla H Al Ali9, Nicholas Short2, Naval Daver5, Mark J. Routbort1, Joseph D. Khoury10, Keyur Patel6, Irene Ganan-Gomez2, Yue Wei2, Gautam Borthakur2, Farhad Ravandi2, Kim-Anh Do2, Kelly A. Soltysik2, Olivier Lichtarge3, L. Jeffrey Medeiros1, Hagop Kantarjian2, and Guillermo Garcia-Manero2

Dear Editor,

The prognosis of TP53-mutated myelodysplastic syndromes (MDS) can be heterogeneous. TP53-mutated MDS with low variant allele frequency (VAF), without complex karyotype (CK), and those with mono-allelic TP53 alterations have significantly improved outcomes1–3. TP53 mutations are diverse and distributed across the codons of the entire coding region4. Different types of TP53 mutations lead to distinct functional consequences (such as oncogenic gain-of-function, protein loss-of-function with dominant-negative effect etc5–7), that likely influence disease biology and outcome, either independently or by influencing known variables such as VAF and allelic state2,3. Until now, the relationship between various TP53 mutations and genomic/phenotypic features including outcomes is not well-characterized. This knowledge is important to assess the efficacy of novel therapeutic strategies that restore TP53 function8.

Evolutionary Action score (EAp53) is a computationally-derived score to quantify the deleterious impact of different missense TP53 mutations based on (A) phylogenetic divergence of the mutated sequence position [evolutionary trace (ET)] and (B) perturbation due to amino acid (AA) substitution9. EAp53 score ranges between 0 and 100, a higher score indicates a worse impact, and 0 indicates wild-type function. EAp53 score has been shown to be an objective, reliable prognostic biomarker in patients with head and neck (H&N) and colorectal cancers10–13. Here, we used the EAp53 scoring system to evaluate the impact of different types of missense TP53 mutations on clinico-pathologic and genomic features in MDS.

We identified 270 patients with newly-diagnosed MDS or oligoblastic AML (<30% blasts) with ≥1 missense TP53 mutation(s) at baseline detected by next-generation sequencing (Fig. 1A). The median TP53 VAF was 33.9 (1–94.4); 165 (61%) had multi-allelic TP53 alterations. Majority were treated with hypomethylating agents (HMA). Informed consent was obtained, the study was performed per institutional-approved protocols in accordance with the Declaration of Helsinki. See Supplementary Materials for detailed methodology.

Baseline characteristics are in Table S1. The median EAp53 score was 79 (4.2–97.9) (Fig. 1B). A higher EAp53 score correlated with worse OS ($p = 0.087$; HR 1.06 per 10-point increase [95%CI:1.01–1.13]). Using Recursive-Partitioning-And-Regression-Trees, EAp53 score $>52$ predicted for worse OS (Fig. 1C) generating 2 risk-groups: low-EAp53 [$EAp53 \leq 52; \ n = 17 (6\%)$] and high-EAp53 [$>52; \ n = 253, 94\%$]. The median OS for low-EA-MDS vs. high-EA-MDS was 47.8 vs.
10 months ($p = 0.01$; HR: 2.6 [1.22–5.56]). EAp53 score of 75, previously described in TP53-mutated H&N squamous cell carcinoma, did not show a survival difference in MDS. By univariate analysis, high-EAp53 (>52), TP53 VAF, number of TP53 mutations, IPSS-R score, CK/monosomal karyotype (MK), higher serum LDH and creatinine, lower platelet, hemoglobin, and serum albumin associated with worse OS. Neither TP53 allele state nor del(17p) associated with OS. By multivariable analysis, the EAp53 risk retained the independent predictive value for OS along with IPSS-R score and serum albumin, but not TP53 VAF or the number of TP53 mutations (CK excluded due to a strong association with EAp53 score; Fig. 1D; Table S2). EAp53 risk was the only independent predictor of AML transformation. EAp53 risk did not affect transformation-free survival, relapse-free survival, overall response, and complete remission rates (Table S3).
Next, we explored the clinicopathologic and cytogenomic differences between low-EA-MDS and high-EA-MDS (Table S4). Higher EAp53 score (as a continuous variable) positively correlated with multiple TP53 mutations (\(p = 0.00062\)), higher platelet (\(p = 0.041\)), and serum fibrinogen (\(p = 0.009\)), and negatively correlated with concurrent RUNX1 (\(p = 0.038\)) and EZH2 (\(p < 0.001\)) mutations. When stratified, low-EA-MDS had fewer cytogenetic abnormalities (median 3 vs. 7, \(p = 0.019\)), lower frequency of CK (\(p = 0.0241\)), and MK (\(p = 0.0043\)). High-EAp53-MDS had a higher frequency of total multiple TP53 mutations (32% vs. 6%, \(p = 0.027\)) and multi-allelic TP53 alterations (63% vs. 29%, \(p = 0.0087\)), suggesting that the type of mutation dictates the degree of karyotypic complexity. Patients with gain-of-function TP53 mutations (R175, R248, R273, all noted only in high-EA-MDS) showed no significant outcome difference compared to rest (Fig. S1). Across all genes, the median mutation number (including TP53) in low-EAp53 and high-EAp53 was 3 and 1 (\(p = 0.000002\)). A higher proportion of low-EAp53 patients had additional gene mutations (63% vs. 33%; \(p = 0.05\)), involving NRAS and RUNX1 (\(p = 0.02\)) and a trend for higher frequencies of NPM1, WT1, and ASXL1 mutations (Fig. 1E; Fig. S2). There were no significant differences in the median TP53 VAF, distribution of IPSS-R, therapy-related, or treatment characteristics.

The observed distinctive clinical, cytogenetic, and mutation characteristics provide support to the clinical validity of EAp53 scoring and confirm that low and high-EAp53 do not reflect different positions on the early to late disease trajectory. The presence of at least 1 additional gene mutation, frequently NRAS, in low-EA-MDS corroborates the leukemogenic role of RAS. These additional hits potentially modify the phenotype and outcome of low-EA-MDS. The need for additional hits in high-EA-MDS is abrogated by chromosomal aneuploidies, involving chromosomes 17 and 5, that harbor negative regulators of the RAS pathway.14

We then assessed the downstream effect of the EAp53 score using immunohistochemical TP53 protein expression (low-EAp53: \(n = 10\); median EAp53: 27.9; high-EAp53: \(n = 20\); 84.8). The median H-scores (multiplied score of percent positivity and intensity) for wild-type (6.4), low-EAp53 (47.5), and high-EAp53 (157.5) were significantly different (\(p < 0.05\)) (Fig. 2A–D). These results are in accord with the mRNA studies in squamous cell carcinoma cells where low-EAp53 cells partly retained residual TP53 function.10,11 H-score correlated with TP53 VAF (\(p = 0.00015\); rho(\(p = 0.61\)).

Since protein function is further modulated by the 3D location of the residue, we performed protein structural analysis using the crystal structure of the TP53-core-domain in complex with DNA (PDB ID: 4HJE; PyMOL molecular visualization). We hypothesized that this may explain the variable survival rates noted in some high-EA-MDS patients with similar EAp53 scores. All the TP53 mutations of this cohort mapped to the evolutionarily important sites of the TP53-core-domain. When segregated based on survival of 10 months, TP53 variants with poor-survival (OS < 10 months) formed two clusters: a large cluster interfacing the DNA-binding site and a small cluster formed by residues V157, Y220, L257, and E258, showing that structure location further stratifies the outcome (Fig. 2E, F). Analysis with different survival cut-offs yielded the same results.

Following this, using serial NGS, we compared the mutational dynamics of low vs. high-EA TP53 mutations during disease evolution and therapy. Among 9 low-EAp53, 2 of 3 (67%) who achieved at least partial response showed mutation clearance. The remaining showed persistence of the same TP53 mutation with additional mutations in NRAS (Fig. 2G), KRAS, RUNX1, IDH1, and JAK2. None acquired new TP53 mutations. Among 36 high-EAp53 MDS, 5 of 11 (45%) who achieved at least morphologic CR showed mutation clearance. Rest had persistence of the original TP53 mutation(s) (Fig. 2H); 1 acquired 3 additional TP53 mutations (also high-EA). Only 2 patients (8%) acquired new mutations in NRAS, IDH1, and TET2.

Finally, we verified the biological relevance of EAp53 scoring using other independent computational methods. CADD and REVEL segregated the same prognostic subgroups (but not DANN, Polyphen 2, MutPred, PROVEAN, SIFT; Fig. S3). To validate the EAp53 cut-off of 52, we used an independent single-center cohort of 62 MDS patients, selected using the same criteria and treated using HMAs. There were 3 (5%) low-EA-MDS patients [p. Y220H, p.F134L, p.R209W] with a longer median OS (112 vs. 32 months, \(p = 0.25\)) compared to high-EA-MDS (Fig. S4). CADD and REVEL could not separate these patients, suggesting that the EAp53 method was superior. When study and validation cohorts were merged, all 3 methods were concordant [EAp53, \(p = 0.0103\); REVEL, \(p = 0.03\); CADD \(p = 0.006\); Fig. S5].

The study has a few limitations. Although this is a large retrospective study, the inherent low frequency of low-EAp53 MDS (~6%) warrants validation in multi-center cohorts. While the possibility that some of the low-EAp53 variants represent rare single nucleotide polymorphisms (SNP) cannot be completely excluded, to the best of our knowledge, all low-EAp53 variants were clinically reported by the laboratory after extensive curation using literature, online databases including COSMIC, dbSNP, 1000 genome, EXAC, ClinVar and in-silico prediction tools. Repeat NGS on 9 (53%) patients showed clearance or significant variations in the TP53 VAFs, strongly suggesting somatic origin. TP53 VAF was not independently prognostic in this study. Unlike other reports12, we note...
that this cohort is unique because it excluded patients with nonsense/frameshift \textit{TP53} mutations that are likely to have higher VAF and multi-allelic \textit{TP53} alterations due to a loss-of-function phenotype. Further, VAFs were not normalized based on copy number. The study did not assess copy-neutral loss-of-heterozygosity that could explain the lack of association with \textit{TP53} allele status.

In conclusion, this is the first study to show the independent prognostic value of the EAp53 score, thereby expanding the previously established genomic attributes impacting the outcomes of \textit{TP53}-mutated MDS\textsuperscript{1–3}. While VAF and karyotype are dependent on the aspirate quality (often compromised by fibrosis in \textit{TP53}-mutated MDS) and vary with disease evolution and therapy, EAp53 score
is mutation-dependent, stable predictive biomarker, not influenced by therapy or time for baseline risk-stratification. These findings are important in lieu of novel mutation type-specific therapeutic strategies. Low-EAp53 mutants may benefit from strategies that utilize residual TP53 function while small molecules, such as APR-246 and COTI-2, which restore TP53 function may be appropriate for high-EAp53 mutants. Together with structural mapping, the EAp53 score can guide treatment. Overall, the study shows that the EAp53 score can identify prognostic subsets within TP53-mutated MDS and facilitate a personalized therapeutic approach.

Acknowledgements

This work was supported in part by the Institutional start-up funds awarded to R.K.-S., Institutional Research Grant awarded to R.K.-S., University of Texas MD Anderson Cancer Center Support Grant CA016672 and by generous philanthropic donations to the University of Texas MD Anderson MDS/AML Moon Shot Program.

Author details

1Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 3Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States. 4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 5Wallerian Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States

Data availability

The datasets generated during and/or analyzed during this study are not publicly available due to patient privacy concerns but are available from the corresponding author on reasonable request.

Conflict of interest

K.S.: This author declares an advisory role with Pfizer, Japan, Novartis, and Daiichi-Sankyo. E.J.: This author declares research support from and consultancy with AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Pfizer, and Takeda. T.K.: This author reports honoraria from Novartis and Agios; grants and honoraria from Pfizer, AbbVie, Genentech, and Jazz Pharmaceuticals; and research grants from Bristol Myers Squibb, Amgen, AstraZeneca, Celgene, Incyte, and Ascenta. M.A.: This author declares research grants and a consultancy with Daiichi-Sankyo; consultancy with Jazz Pharmaceuticals, Celgene, Amgen, and AstraZeneca; equity ownership with Reata, Aptose, Eutropics, SentiBio, Oncoceutics, and Oncolyze; and an advisory role with the Center for Drug Research and Development, Cancer UK, the Leukemia and Lymphoma Society, and Bioline. G.B.: This author declares research support from Oncoceutics, Xbiotech USA, Arvinas, Polaris, AstraZeneca, Bristol Myers Squibb, Cyclacel, GlaxoSmithKline, Janssen, Incyte, AbbVie, and Novartis; personal fees from Argenx, PTC Therapeutics, BioTheryX, Nkarta, Inc., Treadwell Therapeutics, and Curo Science; and personal fees and research support from FTC Therapeutics and BioLine Rx. H.K.: This author declares research support and an advisory role with Actinium, and research support from AbbVie, Agio, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. G.G.-M.: This author declares research support and an advisory role with Amphilvena, Astex, and Celgene, and research support from AbbVie, H3 Biomedicine, Helios, Onconova, Merck, and Novartis. The remaining authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1038/s41408-021-00446-y.

Received: 14 December 2020 Revised: 16 February 2021 Accepted: 19 February 2021

Published online: 06 March 2021

References

1. Salmin, D. A. et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukem Res 30, 666–673 (2016).
2. Montalban-Bravo, G. et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4, 482–495 (2020).
3. Bernard, E. et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat. Med. 26, 1549–1556 (2020).
4. Bykov, V. J. N., Erikson, S. E., Bianchi, J. & Wilman, K. G. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer 18, 89–102 (2018).
5. Yue, X. et al. Mutant p53 in cancer: accumulation, gain-of-function, and therapy. J. Mol. Biol. 429, 1595–1606 (2017).
6. Böttcher, S. et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365, 599–604 (2019).
7. Sabapathy, K. & Lane, D. P. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat. Rev. Clin. Oncol. 15, 13–30 (2018).
8. Zhang, Q., Bykov, V. J. N., Wilman, K. G. & Zawacka-Pankau, J. APR-246 reacts with mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 9, 439 (2018).
9. Katsonis, P. & Lichtarge, O. A formal perturbation equation between genotype and phenotype determines the Evolutionary Action of protein-coding variations on fitness. Genome Res. 24, 2050–2058 (2014).
10. Neskey, D. M. et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 75, 1527–1536 (2015).
11. Osman, A. A. et al. Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Res. 75, 1205–1215 (2015).
12. Chun, Y. S. et al. Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann. Surg. 269, 917–923 (2019).
13. Katsonis, P. & Lichtarge, O. CAGI5: objective performance assessments of predictions based on the evolutionary action equation. Hum. Mutat. 40, 1436–1454 (2019).
14. Zhao, Z. et al. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat. Genet. 47, 539 (2015).
15. Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017).